Amicus Therapeutics Inc
(FRA:AM6)
€
9.3
0.2 (2.2%)
Market Cap: 2.82 Bil
Enterprise Value: 3.01 Bil
PE Ratio: 0
PB Ratio: 16.43
GF Score: 78/100 Amicus Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 09, 2021 / 09:30PM GMT
Release Date Price:
€8.75
(+7.36%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP
Good afternoon. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're really pleased today to have Amicus Therapeutics with us, for which John Crowley, CEO, is joining us. John, thank you for joining today.
John F. Crowley
Amicus Therapeutics, Inc. - Chairman & CEO
Yes. Hi, Salveen. Of course. Good evening, everybody.
Questions & Answers
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP
Maybe to start here, maybe we'll start with the AT-GAA. You expect to complete the rolling BLA submission for the drug in Pompe disease in the second quarter. Given the results of the Phase III study with regard to what you saw at the primary endpoint and the secondary endpoint, what are the key factors contributing to your confidence in approval? And what are the key risks?
John F. Crowley
Amicus Therapeutics, Inc. - Chairman & CEO
Yes. Thanks, Salveen.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot